In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US House Expected To Vote On Device-Tax Bill Tuesday

Executive Summary

The House is expected to vote on a standalone bill to repeal the medical device tax July 24. Industry groups are hoping for a quick and easy passage of the bill so it doesn't become entangled in other political battles, such as the upcoming debate on a new Supreme Court justice.

You may also be interested in...



Medtech Groups To Blitz Congress Before Expected House Device Tax Vote

After Minnesota Congressman Erik Paulsen seemed to confirm plans for a floor vote on the medical device excise tax repeal before August, medical device lobby groups say they are rallying to get the deal done before it gets pushed off the agenda by the upcoming US Supreme Court nomination process.

Massive Family Dollar Rat Infestation Leads To Multi-State Recall

The US FDA found more than 2,000 rats at an Arkansas Family Dollar distribution center, leadingto a six-state recall for products including feminine hygiene products, contact lens cleaners and face masks.

Digital Health Roundup: Exec Chats With Illumina, Bloom, AngelMed; M&A, Funding; FDA Down-Classifies Apps

In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights IBM Watson Health’s divestiture and other financing news, Exec Chats with Illumina, AngelMed and Bloom, Philips’ new hand-held ultrasound device and autonomous robotic surgery, as well as the latest FDA news on digital health.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT123021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel